Soros Fund Management’s Novavax NVAX Stock Holding History

Soros Fund Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,515	Closed	-$156K	–	223
2016 Q1	$156K	Buy	+1,515	New	+$163K	﹤0.01%	219
2013 Q4	–	Sell	-28,650	Closed	-$1.81M	–	272
2013 Q3	$1.81M	Buy	+28,650	New	+$1.61M	0.02%	200

Other funds holding NVAX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Soros Fund Management's NVAX Position: Q2 2016 in Review

Soros Fund Management sold out of Novavax (NVAX) in Q2 2016, closing a stake of 1,515 shares — an estimated $156K sold.

Soros Fund Management first reported a position in NVAX in Q3 2013 and held it in 2 quarters. The position peaked at $1.81M in Q3 2013. 186 funds tracked by Wall St. Rank hold NVAX as of Q2 2016.

Soros Fund Management reported no remaining Novavax position as of Q2 2016 after selling out during the quarter.
Soros Fund Management sold 1,515 Novavax shares in Q2 2016, an estimated $156K.
Soros Fund Management first reported a position in Novavax in Q3 2013 and held it in 2 quarters.
Soros Fund Management's Novavax position peaked at $1.81M in Q3 2013.
186 funds tracked by Wall St. Rank held Novavax as of Q2 2016.

Based on Soros Fund Management's 13F filing for Q2 2016, filed 15 Aug 2016.